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Abstract 
Aim: To characterize lipid profiles in women with different gestational diabetes mellitus (GDM) 
physiologic subtypes.  
Methods: We measured seven lipid markers (total cholesterol, LDL, HDL, triglycerides, non-esterified 
fatty acids (NEFA), ApoA, ApoB) in fasting plasma collected in a prospective cohort of 805 pregnant 
women during second trimester. We estimated insulin sensitivity and secretion using oral glucose 
tolerance test-based validated indices. We categorized GDM physiologic subtypes by insulin sensitivity 
and secretion defects defined as values below the 25th percentile among women with normal glucose 
tolerance (NGT), as previously established. We compared lipid markers across NGT and GDM subtypes. 
We explored associations between lipid markers and newborns anthropometry in the overall group and 
stratified by glucose tolerance status.  
Results: Among 805 women, 67 (8.3%) developed GDM. Women with GDM had higher body mass index 
(BMI; 29.3 vs. 26.6 kg/m2), while ethnicity (97.3% vs. 97.0% European ancestry) and age (28 vs. 29 
years) were similar. In comparison to women with NGT, women with GDM characterized by a 
predominant insulin sensitivity defect had significantly higher triglycerides (2.20 vs. 1.82, P=0.002), 
lower HDL (1.64 vs. 1.90, P=0.01) and higher NEFA (0.34 vs. 0.24, P<0.0001). GDM women with a 
predominant insulin secretion defect differed from women with NGT with respect to NEFA (0.32 vs. 
0.24, P=0.003) while other lipid markers were similar. These associations remained significant after 
adjusting for maternal age and BMI. Greater maternal levels of NEFA were associated with higher birth 
weight z-scores in women with an insulin secretion defect (BMI-adjusted r=0.58, P=0.01). We did not 
find significant associations between other lipid markers and newborn anthropometry in other groups. 
Conclusion: Women with GDM have distinct lipid profiles based on their GDM physiologic subtype 
which may not be apparent when investigating GDM as a single group.  
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1. Introduction 
Pregnancy markedly alters lipid metabolism. The first trimester is characterized by increased 
lipogenesis; later in pregnancy there is a shift to a more lipolytic state, in accordance with fetal growth 
requirements [1,2]. Previous studies have suggested that pregnancies with gestational diabetes mellitus 
(GDM) are characterized by more severe hyperlipidemia as compared to pregnancies in which normal 
glucose tolerance (NGT) is maintained, but reports are inconsistent regarding which lipids are elevated 
[3-6].  A possible explanation is that GDM is a heterogeneous condition. We previously demonstrated 
that GDM can be subdivided into three physiologic subtypes [7].  We also observed that women with an 
insulin-sensitivity defect had higher complication rates at delivery suggesting other fuels may contribute 
to macrosomia and related birth complications [7]. However, it is unknown if lipids differ among GDM 
physiologic subtypes. Thus, the purpose of this study was to characterize gestational lipid profiles among 
three physiologic GDM subtypes and compare them to NGT women.  
2. Methods 
2.1 Study Details 
This study used data from the Genetics of Glucose regulation in Gestation and Growth (Gen3G) 
cohort, a prospective cohort study of maternal-child pairs followed from the first trimester through 
delivery, previously described [8]. The ethics committee at Centre Hospitalier Universitaire de 
Sherbrooke (CHUS) approved the study and all participants provided written informed consent.  
2.2 Gestational Diabetes Mellitus Status 
After excluding women with pre-existing diabetes at enrollment, we classified women as having 
GDM if their second trimester 75g oral glucose tolerance test (OGTT) based on international criteria [9]. 
We used plasma glucose and insulin values obtained at 0, 60 and 120 minutes during OGTT to calculate 
insulin sensitivity [10] (Matsuda index) and secretion indices [11-12] (Stumvoll first-phase estimate). We 
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defined women as having insulin-sensitivity defect if their Matsuda insulin sensitivity index was below 
the 25th percentile of the Matsuda index distribution (GDM-Sensitivity); we defined women as having 
insulin-secretion defect if their Stumvoll insulin secretion was below the 25th percentile of the Stumvoll 
estimate distribution (GDM-Secretion) (both distributions determined among NGT women) as previously 
described [7]. We categorized women with both defects as GDM-mixed.  
2.3 Measurements  
We obtained ≥8-hour fasting samples during the second trimester visit for the following biomarkers: 
total cholesterol (TC), high-density lipoprotein-cholesterol (HDL), low-density lipoprotein-cholesterol 
(LDL), Apolipoprotein A and B (Apo A and B), triglycerides, non-esterified fatty acids (NEFA), fasting 
glucose, HbA1c and insulin using methods described elsewhere [13]. The CHUS biomedical laboratory 
measured fasting TC, HDL, and triglycerides using a colorimetric method (Johnson & Johnson Clinical 
Diagnostics) and calculated LDL using Friedewald’s equation. We measured NEFA levels [minimum level 
of detection of 0.0014 mM; intra-assay coefficients of variation (CV) 0.8%] using a colorimetric assay 
(Wako Chemicals). We excluded three NGT women whose LDL >7.0 mmol/L as this was suggestive of 
familial hypercholesterolemia. 
2.4 Statistical Analysis 
We presented participants’ characteristics as medians (interquartile range) for continuous measures 
and frequencies for categorical values. We used the rank-sum test to compare the GDM group overall 
with the NGT group. We used Kruskall-Wallis tests for continuous variables and Fisher exact tests for 
categorical variables to compare differences across groups. When P values from Kruskall-Wallis or Fisher 
exact tests were <0.05, we did pairwise comparisons between groups using Dunn’s tests [13] or Fisher 
exact tests with Bonferroni correction of P values.  We used linear regression to control for maternal 
BMI and age, transforming non-normally distributed dependent variables with either the natural-log or 
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square-root transformations to achieve normality prior to regression. We assessed the relationships 
between NEFA and insulin sensitivity, secretion and oral disposition indices (controlling for second 
trimester maternal BMI) and all lipids and birth weight using pairwise and partial correlation analyses 
(controlling for BMI or gestational weight gain). We considered a two-tailed P<0.05 statistically 
significant. We performed analyses using SAS version 9.4 (Cary, North Carolina) and Stata version 15 
(Stata Corp LP, College Station, Texas). 
3 Results 
We included 805 women in our current analyses, 67 (8.3%) diagnosed with GDM (34 GDM-
Sensitivity, 20 GDM-Secretion and 12 GDM-Mixed) and 739 who maintained normoglycemia. GDM-
Sensitivity women had a significantly higher BMI as compared to NGT women [7].  There was a higher 
frequency of previous GDM or macrosomia among GDM-Secretion vs. NGT women (Table 1). Additional 
subtype differences in characteristics have been reported previously [7].  
GDM women had higher median triglycerides and NEFA vs. NGT women: 1.97 vs. 1.82 (P=0.02) and 
0.33 vs. 0.24 (P<0.0001), respectively (Table 1).  Regarding GDM subtypes, we noted differences in 
NEFA, triglycerides, HDL, LDL and TC across groups (Table 1 and Figure 1). Compared to NGT women, 
GDM-Sensitivity women had lower HDL (1.64 vs. 1.90, P=0.01) and higher triglycerides (2.20 vs. 1.82, 
P=0.002) and NEFA (0.34 vs. 0.24, P<0.0001). GDM-Sensitivity women also had lower HDL and higher 
triglycerides than GDM-Secretion women (Figure 1). These differences remained statistically significant 
after maternal BMI and age adjustment. In contrast, we did not find significant differences in most lipid 
markers in GDM-Secretion compared to NGT women except for NEFA (0.32 vs. 0.24, P=0.003). NEFA 
levels in GDM-Mixed women were similar to other subtypes (Figure 1) and demonstrated higher levels 
but not statistically different from NGT women. GDM-Mixed women had higher TC compared to NGT, 
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and higher TC and LDL compared to GDM-Sensitivity and GDM-secretion (Figure 1); these associations 
were maintained after adjustments for maternal age and BMI.  
To further our understanding of the pathophysiologic role of NEFA in pregnancy, we evaluated the 
relationship between NEFA and the oral disposition index (DIo). After controlling for BMI, we observed a 
weak negative partial correlation in the NGT group (r=-0.14, P=0.001). We did not find significant 
correlations between NEFA and DIo in overall GDM or in any GDM subtype. We did not find significant 
associations between NEFA and insulin sensitivity and secretion indices in women with NGT or GDM. 
Finally, we explored links between lipids and newborn anthropometry: we did not find significant 
relationships between triglycerides, HDL, LDL, TC and birth weight by glycemic status (adjusted for 
maternal BMI or gestational weight gain). However, we found that greater maternal NEFA levels were 
associated with higher birth weight z-scores in GDM-Secretion subtype (adjusted for BMI or gestational 
weight gain, r=0.58, P=0.01). 
4 Discussion 
We found that the lipid profile differs between GDM and NGT women and demonstrated 
heterogeneity in lipid profiles between GDM physiologic subtypes. Women with GDM-Sensitivity defect 
had higher triglycerides and lower HDL when compared with NGT or GDM Secretion women. 
Conversely, the lipid profiles of women with GDM-Secretion defect did not differ significantly from those 
of NGT women, apart from NEFA which were elevated in all GDM subtypes.  TC and LDL were 
significantly higher in the GDM-Mixed subtype compared to the GDM-Secretion and GDM-Sensitivity 
subtypes.   
By investigating GDM subtypes, we demonstrated striking differences in lipid profiles that were not 
apparent when investigating GDM as one group, with most prominent differences for women with 
GDM-Sensitivity defect. Prior literature suggests that NEFA and triglycerides, after crossing the placenta, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
are released into fetal circulation and may serve as fetal fuel in addition to glucose [14-15]. We expected 
both to be higher in GDM-Sensitivity, since we observed higher birth weight in this subtype [7]. 
However, our finding of elevated NEFA across all GDM physiologic subtypes indicates other factors could 
be influencing birth weight.  Yet we did not observe any significant relationship between birth weight 
and triglycerides, HDL, LDL and TC, thus other lipids should be investigated.   
Study strengths include using validated indices to estimate insulin sensitivity and secretion, and 
previously characterized GDM physiologic subtypes allowing us to observe distinct lipid profiles. Study 
limitations include most participants were of European origin, limiting generalizability, and small sample 
sizes contributing to limited power and lack of statistically significant differences. We did not assess 
glycemia at the end of pregnancy, but all GDM women were treated at the same multidisciplinary clinic 
and proportion of insulin treatment did not differ across GDM subtypes [7]. 
5 Conclusions 
Our results demonstrate that GDM physiologic subtypes differ in their gestational lipid profiles, 
underscoring the presence of physiologic heterogeneity in GDM.  Future studies should investigate small 
lipid fractions and metabolites in GDM physiologic subtypes and their role in fetal overgrowth. 
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Table 1. Characteristics and lipid values of women with NGT or GDM, by physiological subtype 
 GDM-Secretion 
Median (IQR)/n (%) 
P
†
 GDM-Mixed 
Median (IQR)/n 
(%) 
P
†
 GDM-Sensitivity 
Median (IQR)/n 
(%) 
P
†
 NGT 
Median (IQR)/n (%) 
P* All GDM 
Median (IQR) 
P
ǂ
 
n
+
 20 (29.9% of GDM) --- 12 (17.9% of 
GDM) 
--- 34 (50.7% of 
GDM) 
--- 739 (91.8% of total 
n) 
--- 67 (8.3% of   total 
n) 
--- 
Age (years) 30 (28-32) --- 31 (23-33) --- 28 (25-35) --- 28 (25-31) 0.16 29 (26-33) 0.05 
% European Descent 18 (90.0%) --- 12 (100.0%) --- 34 (100.0%) --- 714 (97.1%) 0.22 65 (97.0%) 0.95 
% Nulliparous 5 (25.0%) --- 4 (33.3%) --- 17 (50.0%) --- 382 (51.8%) 0.07 27 (40.3%) 0.07 
% Patient History of GDM or 
macrosomia 
8 (40.0%) 0.001 3 (25.0%) 0.23 5 (14.7%) 0.61 62 (8.4%) 0.0001 16 (23.9%) <.0001 
First-trimester visit           
Gestational age (weeks) 8.8 (7.5-10.8) --- 10.2 (8.2-12.1) --- 9.4 (7.2-11.6) --- 9.2 (8.1-11.4) 0.85 9.3 (7.4-12.0) 0.89 
BMI (kg/m
2
) 21.9 (20.7-26.0) 0.15 25.3 (21.3-29.8) 0.98 30.1 (26.9-37.7) <.0001 23.9 (21.5-27.5) <.0001 27.0 (22.0-32.4) 0.002 
Second-trimester visit           
Gestational age (weeks) 26.4 (25.9-27.7) --- 26.2 (25.3-27.8) --- 26.3 (25.6-26.6) --- 26.2 (25.6-27.1) 0.65 26.3 (25.6-34.5) 0.91 
BMI (kg/m
2
) 25.0 (23.7-28.3) 0.21 28.7 (24.6-32.8) 0.65 32.3 (28.9-40.9) <.0001 26.6 (24.2-30.1) <.0001 29.3 (25.6-34.5) 0.0004 
Insulin sensitivity (Matsuda) 7.4 (6.2-8.5) >0.99 5.4 (4.7-5.5) 0.0003 2.9 (2.3-4.0) <.0001 7.9 (5.8-11.2) <.0001 4.6 (2.9-6.2) <.0001 
Insulin secretion (Stumvoll) 594 (501-739) <.0001 748 (694-870) <.0001 1364 (1063-1677) 0.0003 1121 (934-1286) <.0001 969 (676-1368) 0.004 
DIo 4491 (3947-5318) <.0001 4082 (3824-4374) <.0001 4038 (3655-4613) <.0001 8557 (6797-12004) <.0001 4144 (3760-4850) <.0001 
Lipids           
Fasting NEFA (nmol/L) 0.32 (0.27-0.38) 0.01 0.32 (0.23-0.36) 0.17 0.34 (0.28-0.39) <.0001 0.24 (0.18-0.31) <.0001 0.33 (0.26-0.38) <.0001 
Triglycerides (mmol/L) 1.75 (1.33-1.85) 0.54 2.04 (1.71-2.66) 0.18 2.20 (1.73-2.78) 0.004 1.82 (1.48-2.24) 0.001 1.97 (1.58-2.61) 0.02 
HDL cholesterol (mmol/L) 2.20 (1.79-2.30) 0.29 1.92 (1.46-2.33) >0.99 1.64 (1.42-2.03) 0.01 1.90 (1.63-2.18) 0.01 1.89 (1.46-2.22) 0.28 
LDL cholesterol (mmol/L) 3.26 (2.92-3.52) 0.29 4.39 (3.31-5.43) 0.07 2.99 (2.18-3.81) 0.06 3.41 (2.83-4.03) 0.01 3.24 (2.67-3.82) 0.19 
Total cholesterol (mmol/L) 6.10 (5.55-6.47) >0.99 7.15 (6.52-7.88) 0.01 5.98 (5.01-6.61) 0.28 6.18 (5.51-6.92) 0.01 6.23 (5.34-6.96) 0.68 
Apolipoprotein A (mmol/L) 2.21 (2.08-2.36) --- 2.16 (2.03-2.35) --- 2.08 (1.84-2.20) --- 2.11 (1.93-2.30) 0.22 2.17 (1.91-2.24) 0.74 
Apolipoprotein B (mmol/L) 1.10 (1.08-1.25) --- 1.52 (1.10-1.60) --- 1.19 (0.96-1.38) --- 1.18 (1.03-1.38) 0.18 1.14 (1.08-1.38) 0.98 
NGT, normal glucose tolerance; GDM, gestational diabetes mellitus; IQR, interquartile range; GCT, glucose challenge test; DIo, oral disposition index; NEFA, non-esterified 
fatty acid. *Differences across groups were compared using the Kruskall-Wallis test for continuous variables and the Fisher exact test for categorical variables. †When 
the P values from the Kruskall-Wallis test or Fisher exact test were <0.05, pairwise comparisons were made between the NGT group and each of the GDM subtypes 
using Dunn’s test or Fisher exact test. P values were adjusted using the Bonferroni method and are presented in the third, fifth and seventh columns. ǂDifferences 
between the All GDM group and the NGT group were compared using the rank sum test with P values given in the eleventh column. +Missing data on second-
trimester LDL (n=34) and second-trimester HDL (n=28); all other variables had data missing for ≤5 participants. There were a total of 67 participants with GDM, 
however one participant could not be categorized into a subtype leaving a total of 66 available for subtype analyses. 
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Highlights: 
 
 Women with gestational diabetes have distinct lipid profiles by physiologic subtype 
 Defect in insulin sensitivity is characterized by low HDL and high triglycerides 
 Mixed defect of insulin secretion and sensitivity is characterized by high total cholesterol 
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